897 results match your criteria: "Japan H.H.; and Fukuoka Renal Clinic[Affiliation]"

Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.

Ann Surg Oncol

July 2024

Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.

Purpose: Pancreatic ductal adenocarcinoma (PDAC) patients with normal carbohydrate antigen (CA) 19-9 levels can have early-stage cancer or advanced cancer without elevation of CA19-9 level; estimating their malignant potential is difficult. This study investigated the clinical utility of the combined use of preoperative CA 19-9 and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels in patients with PDAC.

Methods: Patients who underwent curative-intent surgery for PDAC between November 2005 and December 2021 were investigated.

View Article and Find Full Text PDF

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

N Engl J Med

April 2024

From Dana-Farber Cancer Institute and Harvard Medical School (T.K.C.) and Beth Israel Deaconess Medical Center (D.F.M.) - all in Boston; Poznan University of Medical Sciences, Poznan (P.T.), and Provincial Hospital in Torun, Torun (P.S.) - both in Poland; Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Asan Medical Center, University of Ulsan College of Medicine (J.-L.L.) - both in Seoul, South Korea; Beatson West of Scotland Cancer Centre and the University of Glasgow, Glasgow (B.V.), Edinburgh Cancer Centre and the University of Edinburgh, Edinburgh (S.N.S.), and Imperial College Healthcare NHS Trust (N.S.), Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute (T.P.), and Queen Mary University of London (T.P.), London - all in the United Kingdom; Fiona Stanley Hospital, Perth, WA (T.F.), and Maquarie University, Sydney (H.G.) - both in Australia; Fakultní Nemocnice Ostrava, Ostrava (J.H.), and Palacký University and University Hospital Olomouc, Olomouc (B.M.) - all in the Czech Republic; Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Abramson Cancer Center, Penn Medicine, Philadelphia (N.B.H.); Fundación Arturo López Pérez, Santiago, Chile (M.M.); University Hospital Bordeaux-Hôpital Saint-André, Bordeaux (M.G.-G.), Hôpital Européen Georges Pompidou, Université Paris Cité, Paris (S.O.), and Centre Hospitalier Universitaire de Montpellier, Montpellier (D.T.) - all in France; the University of Texas Southwestern Medical Center, Dallas (T.Z., H.H.), and Texas Oncology-Houston, Houston (G.D.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Omsk Clinical Oncology Dispensary, Omsk, Russia (E.K.); the University of Michigan, Ann Arbor (A.A.); the University of Toyama, Toyama, Japan (H.K.); Instituto de Cancer e Transplante de Curitiba, Curitiba, Brazil (A.S.); the London Regional Cancer Program, London Health Sciences Centre, Western University, London, ON, Canada (E.W.); and Merck, Rahway, NJ (J.C., A.E., J.E.B., R.F.P.).

Background: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain.

Methods: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent.

View Article and Find Full Text PDF
Article Synopsis
  • * Three new recurring KMT2A-rearranged groups were identified, and a significant variation in 5-year event-free survival rates was observed across 13 different groups, highlighting the impact of genetic factors on patient outcomes.
  • * The research suggests incorporating five specific adverse-risk KMT2A fusions into current risk stratification models and calls for further studies to confirm the associations
View Article and Find Full Text PDF

Compositions and Microstructures of Carbonated Geopolymers with Different Precursors.

Materials (Basel)

March 2024

Graduate School of Science and Technology for Innovation, Yamaguchi University, 2-16-1 Tokiwadai, Ube 755-8611, Japan.

It is thought that geopolymers are easy to carbonate, especially when they are cured in ambient temperatures. Matrix gel's composition and microstructure, and new products of geopolymers (GPs) after carbonation were investigated in this study on the basis of XRD and SEM-EDS measurements and ternary diagram analysis, which were prepared from low-lime fly ash (FA) and ground granulated blast-furnace slag (GGBS) alone or a blend, as a precursor. The specimens were hardened in a 20 °C environment with alkali activator solution (S/N = 1.

View Article and Find Full Text PDF

Worldwide forest surveys reveal forty-three new species in major Clade 2 with fundamental implications for the evolution and biogeography of the genus and global plant biosecurity.

Stud Mycol

March 2024

Mendel University in Brno, Faculty of Forestry and Wood Technology, Department of Forest Protection and Wildlife Management, Phytophthora Research Centre, 613 00 Brno, Czech Republic.

Article Synopsis
  • A study conducted between 1998 and 2020 identified 43 new species in diverse ecosystems across Europe, Asia, and the Americas, using genetic analysis to classify them into existing and new subclades within a major clade.
  • The evolutionary history of this clade includes separations before and after the breakup of Gondwana, leading to distinct groups with varying lifestyles, such as soilborne and aerial species.
  • High levels of hybridization were observed in some subclades, indicating that environmental and breeding systems may encourage the emergence of new species, revealing significant gaps in our understanding of potential pathogen threats to ecosystems.
View Article and Find Full Text PDF

Background: The current management of patients with stroke with intravenous thrombolysis and endovascular thrombectomy is effective only when it is timely performed on an appropriately selected but minor fraction of patients. The development of novel adjunctive therapy is highly desired to reduce morbidity and mortality with stroke. Since endothelial dysfunction is implicated in the pathogenesis of stroke and is featured with suppressed endothelial nitric oxide synthase (eNOS) with concomitant nitric oxide deficiency, restoring endothelial nitric oxide represents a promising approach to treating stroke injury.

View Article and Find Full Text PDF

We conducted a randomized phase 3 study to investigate the efficacy and safety of GH treatment in prepubertal Japanese patients with short stature due to deficiency. The patients were randomly allocated to the GH-GH group (n = 10), in which the patients were treated with GH (0.35 mg/kg/wk) subcutaneously once daily for 24 mo, or the no-treatment (NT)-GH group (n = 9), in which the patients were untreated for the first 12 mo and then administered the same dosage of GH for the next 12 mo.

View Article and Find Full Text PDF

Functional insights of Tyr37 in framework region 2 directly contributing to the binding affinities and dissociation kinetics in single-domain VH antibodies.

Biochem Biophys Res Commun

May 2024

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan; Medical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. Electronic address:

Single-domain VH antibody is regarded as one of the promising antibody classes for therapeutic and diagnostic applications. VH antibodies have amino acids in framework region 2 that are distinct from those in conventional antibodies, such as the Val37Phe/Tyr (V37F/Y) substitution. Correlations between the residue type at position 37 and the conformation of the CDR3 in VH antigen recognition have been previously reported.

View Article and Find Full Text PDF

Despite the known beneficial effects of creatine in treating exercise-induced muscle damage (EIMD), its effectiveness remains unclear. This study investigates the recovery effect of creatine monohydrate (CrM) on EIMD. Twenty healthy men (21-36 years) were subjected to stratified, randomized, double-blind assignments.

View Article and Find Full Text PDF

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

N Engl J Med

March 2024

From the Hematology and Transplant Unit, French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis Hospital (R.P.L., F.S.F.), and Université de Paris (R.P.L.), Paris, Centre Hospitalier Universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse (S.T.), and CHU Lille, Université de Lille, Lille (L.T.) - all in France; the Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen (A.R., F.A.), the Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, and the Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen (J.P.), the University of Ulm, the Institute of Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm (H.S., B. Höchsmann), the Department of Oncology, Hematology, and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (P. Schafhausen), and Elblandklinikum Riesa, Riesa (J.S.) - all in Germany; King's College Hospital NHS Foundation Trust (A.G.K., S.G., R.T.), the National Institute for Health and Care Research and Wellcome King's Clinical Research Facility (A.G.K.), King's College London (A.G.K.), and Novartis Pharmaceuticals (C.T.), London, and St. James's University Hospital, Leeds (M.G., R.J.K.) - all in the United Kingdom; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing (B. Han, C.Y.), the Department of Hematology, Tianjin Medical University General Hospital (R.F., H.L.), and the Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (L.Z.), Tianjin, and China Novartis Institutes for BioMedical Research, Shanghai (Z.W., S.L.) - all in China; the Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo (P. Scheinberg), and ABC Medical School, Santo André (V.A.Q.M.) - both in Brazil; the Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland (J.P.M.); Osaka University Graduate School of Medicine, Suita (Y.U.), Kyoto University Hospital, Kyoto (T.K.), and Japanese Red Cross Society Suwa Hospital, Suwa (M.U.) - all in Japan; Duke University School of Medicine and Duke Cancer Institute, Durham, NC (C.M.C.); Unità Operativa Complessa Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (E.D.B.), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (W.B.), Division of Hematology, University of Turin, Città della Salute e della Scienza, Turin (E.B.), Instituto per lo Studio, la Prevenzione e la Rete Oncologica, and Azienda Ospedaliero-Universitaria Careggi, Florence (R.N.), AORN Moscati, Avellino (L.M., A.M.R.), and University of Naples Federico II, Naples (A.M.R.) - all in Italy; Radboud University Medical Center, Nijmegen, the Netherlands (S.M.C.L.); the Hematology Unit, Department of Medicine, Hospital Umum Sarawak, Kuching (L.P.C.), and the Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu (L.W.L.L.) - both in Malaysia; Hospital Clinic of Barcelona (A.G.) and the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (R.P.L., A.G.K., M.G., W.B., S.T., L.T., F.S.F., L.M., A.M.R.) - both in Barcelona; the Department of Hematology and Oncology and the Department of Clinical Pathology, Hualien Tzu Chi Hospital, the Buddhist Tzu Chi Medical Foundation, and the Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan (W.-H.H.); the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (J.H.J.); Medical College of Georgia, Augusta (A.K.); City of Hope Medical Center, Duarte, CA (V.P.); the Department of Laboratory Medicine, National University Hospital, Singapore (E.-S.Y.); Novartis Pharma (C.K., R.L., M.D.) and Novartis BioMedical Research (A.V.) - both in Basel, Switzerland; and Novartis Healthcare Private, Hyderabad, India (P.B., R.K., S.M.).

Article Synopsis
  • Iptacopan, an oral factor B inhibitor, shows promise in treating paroxysmal nocturnal hemoglobinuria patients suffering from persistent hemolytic anemia, especially those not responding to anti-C5 therapy.
  • In two phase 3 trials, iptacopan significantly improved hemoglobin levels in patients with low baseline hemoglobin (under 10 g/dL), with many experiencing increases of at least 2 g/dL without needing blood transfusions.
  • The results revealed that 85% of patients in the first trial and nearly all in the second trial experienced a notable increase in hemoglobin levels, leading to reduced fatigue and dependency on transfusions.
View Article and Find Full Text PDF

The adoption of artificial intelligence (AI) tools in medicine poses challenges to existing clinical workflows. This commentary discusses the necessity of context-specific quality assurance (QA), emphasizing the need for robust QA measures with quality control (QC) procedures that encompass (1) acceptance testing (AT) before clinical use, (2) continuous QC monitoring, and (3) adequate user training. The discussion also covers essential components of AT and QA, illustrated with real-world examples.

View Article and Find Full Text PDF

Statin Therapy for Secondary Prevention in Ischemic Stroke Patients With Cerebral Microbleeds.

Neurology

April 2024

From the Department of Neurology (L.P.-S., P.C.-R., A.R.-P., A.M.-D., J.M.-F.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Stroke Research Centre (P.S.N., D.W., D.J.W.), Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A., J.G.B.), University College London, United Kingdom; Biomedical Research Institute Sant Pau (M.G.-J., Á.L.-G., G.E.D., D.G.-A.), Barcelona, Spain; UCL Stroke Research Centre (H.D.), Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom; Stroke Research Centre, Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China; Centre for Clinical Brain Sciences (R.A.-S.S.), School of Clinical Sciences, University of Edinburgh, United Kingdom; Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London; Lysholm Department of Neuroradiology, The National Hospital of Neurology and Neurosurgery, Queen Square London; Liverpool Centre for Cardiovascular Science at University of Liverpool (G.Y.L.), Liverpool John Moores University and Liverpool Heart & Chest Hospital, United Kingdom; and Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Denmark; A.A. Martinos Center for Biomedial Imaging (H.A.), Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; Takeda Pharmaceutical Company Limited, Cambridge, MA; Department of Neurology (S.J.), University Hospital Inselspital Bern, University of Bern, Switzerland; Department of Neurology (N.M.B.), Tel-Aviv Sourasky Medical Center; Sackler Faculty of Medicine, Tel-Aviv University, Israel; Department of Neurology (T.G., S.E.); Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Department of Radiology and Nuclear Medicine (D.H.D.-N.), Erasmus MC, Rotterdam, The Netherlands; Department of Cerebrovascular Medicine (M.K., K.T.), National Cerebral and Cardiovascular Centre, Osaka, Japan; Department of Neurology (F.F.), University Hospital of Würzburg, Germany; Stroke and Ageing Research Group (T.G.P.), School of Clinical Sciences at Monash Health; Peninsula Clinical School (V.K.S.), Peninsula Health, Monash University; National Centre for Healthy Ageing, Melbourne, Australia; Department of Neurology (J.H.H.), Yonsei University College of Medicine, Seoul, South Korea; Department of Neurology (H.-J.B.), Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea; The Neurovascular Research Unit and Health Research Board (P.J.K.), Stroke Clinical Trials Network Ireland, University College Dublin; Department of Neurosurgery (T.I.), Kushiro City General Hospital, Kushiro, Japan; Department of Neurology (J.S., S.K.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, The Netherlands; Department of Neurology (Y.Y.), Kansai Medical University, Osaka, Japan; Department of Neurology (D.N.O.), Istanbul Arel University, Turkey; Calgary Stroke Program (E.E.S.), Department of Clinical Neurosciences, Radiology and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary; Centre for Clinical Brain Sciences (J.M.W., F.M.C.), Edinburgh Imaging; and UK Dementia Institute at the University of Edinburgh; Centre for Rural Health (S.D.M.), University of Aberdeen, United Kingdom; Department of Neurology (J.-L.M., D.C.), GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266; Univ. Lille (R.B.), Inserm, CHU de Lille. Lille Neuroscience & Cognition, Lille, France; Memory Aging and Cognition Centre (C.P.C.), Yong Loo Lin School of Medicine, National University of Singapore,; Department of Brain Sciences (R.V.), Imperial College London, United Kingdom; Department of Neurology, Heidelberg University Hospital, Germany; Department of Neurology (N.K.), National Neuroscience Institute, Singapore; Stroke Research Centre (R.J.S.), Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology; Comprehensive Stroke Service, University College London Hospitals NHS Trust, United Kingdom; Department of Neurology (F.-E.D.L.), Donders Institute for Brain, Cognition and Behaviour, Donders Centre for Medical Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Neurology and Stroke Centre (S.T.E.), University Hospital Basel and University of Basel; Neurology and Neurorehabilitation, University Department of Geriatric Medicine FELIX PLATTER; University of Basel, Switzerland; Department of Neurology and Stroke Centre (N.P.), University Hospital Basel and University of Basel; Stroke Center Klinik Hirslanden Zürich, Switzerland; Division of Neurology (Y.O.S.), Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong; Department of Neurology and Stroke Centre (A.Z.), University Hospital Basel and University of Basel, Switzerland; Department of Radiology (J.H.), University Medical Center Utrecht; and Department of Clinical Neurophysiology (W.H.M.), Maastricht University Medical Center/Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands.

Article Synopsis
  • This study looked at whether taking statins, a type of medicine, affects the chances of having a repeat stroke or bleeding in the brain for people who have certain brain issues called cerebral microbleeds (CMBs).
  • They analyzed data from many hospitals and included over 16,000 patients, dividing them into those who took statins and those who didn't.
  • The results showed that people who used statins had a lower risk of having another stroke but didn't show a clear difference in the risk of brain bleeding compared to those who didn't take statins.
View Article and Find Full Text PDF

The primordial ingredient of cuprate superconductivity is the CuO unit cell. Theories usually concentrate on the intra-atom Coulombic interactions dominating the 3d and 3d configurations of each copper ion. However, if Coulombic interactions also occur between electrons of the 2p orbitals of each planar oxygen atom, spontaneous orbital ordering may split their energy levels.

View Article and Find Full Text PDF

Differential Pacing Maneuver From the Vein of Marshall.

Circ Arrhythm Electrophysiol

April 2024

Cardiovascular Center, Yokosuka Kyosai Hospital, Japan (N.K., Y.T., K.O., S.T., E.N., K.T., H.H., A.T.).

Background: Bidirectional mitral isthmus (MI) block is conventionally verified by differential pacing from the coronary sinus (CS) and its sequence change. This study aimed to evaluate the ability of differential pacing from the vein of Marshall (VOM) to detect epicardial MI connections.

Methods: Radiofrequency and VOM ethanol MI ablation were performed with a VOM electrode catheter inserted to the septal side of the ablation line.

View Article and Find Full Text PDF

Background: Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRS) for 5 genetic ancestry groups.

Methods: We derived ancestry-specific and multi-ancestry PRS based on pruning and thresholding (PRS) and ancestry-based continuous shrinkage priors (PRS) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.

View Article and Find Full Text PDF

The intrinsic dynamic and static natures of Pn--X--Pn (Pn = Pn: N, P, As and Sb; X = H, F, Cl, Br and I) in 1a-8c were elucidated with the quantum theory of atoms-in-molecules dual functional analysis (QTAIM-DFA). Species 1a-8c were formed by incorporating X between Pn and Pn of Pn(CHCHCH)Pn (1-4) and Pn(CHCHCHCH)Pn (5-8). The relative stabilities between the symmetric and nonsymmetric structures along with their transition states were investigated.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness of pathological criteria from the JSCCR guidelines for determining the need for additional treatment in patients with pT1 colorectal carcinoma who had undergone local resection.
  • Researchers analyzed data from 4,667 patients and found that those with risk factors for lymph node metastasis had a significantly higher incidence of metastasis and recurrence, while those without risk factors had excellent survival rates.
  • Overall, the findings support the JSCCR criteria, highlighting their importance in identifying low-risk patients who can expect favorable outcomes post-resection.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of PD-1/PD-L1 signaling blockade in treating immune evading hepatocellular carcinoma (HCC) and highlights the issue of unexpected tumor growth known as hyper progressive disease (HPD).
  • A cohort of 198 patients with unresectable HCC was analyzed, comparing those receiving anti-PD-1/PD-L1 monotherapy and those receiving combination therapies with VEGF and anti-CTLA-4 antibodies.
  • Results showed a higher HPD rate in the monotherapy group (10.3%) compared to the combination therapy groups, with the anti-CTLA-4 combination showing no increase in HPD frequency, indicating better outcomes with combination treatments.
View Article and Find Full Text PDF

The recently discovered superconductor UTe is a promising candidate for spin-triplet superconductors, but the symmetry of the superconducting order parameter remains highly controversial. Here, we determine the superconducting gap structure by the thermal conductivity of ultraclean UTe single crystals. We find that the -axis thermal conductivity divided by temperature κ/ in zero-temperature limit is vanishingly small for both magnetic field ‖ and ‖ axes up to / ∼ 0.

View Article and Find Full Text PDF

J-domain proteins: From molecular mechanisms to diseases.

Cell Stress Chaperones

February 2024

Department of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address:

J-domain proteins (JDPs) are the largest family of chaperones in most organisms, but much of how they function within the network of other chaperones and protein quality control machineries is still an enigma. Here, we report on the latest findings related to JDP functions presented at a dedicated JDP workshop in Gdansk, Poland. The report does not include all (details) of what was shared and discussed at the meeting, because some of these original data have not yet been accepted for publication elsewhere or represented still preliminary observations at the time.

View Article and Find Full Text PDF

Inactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary Hypertension.

Circulation

April 2024

State Key Laboratory of Respiratory Health and Multimorbidity (Y.L., X.Q., J.Z., B.L., T.S., X.L., H.H., J.L., Q.T., Y.Z., J.P., P.Y., Y.X., J.W., C.W.).

Background: Pulmonary hypertension (PH) is a progressive cardiopulmonary disease with a high mortality rate. Although growing evidence has revealed the importance of dysregulated energetic metabolism in the pathogenesis of PH, the underlying cellular and molecular mechanisms are not fully understood. In this study, we focused on ME1 (malic enzyme 1), a key enzyme linking glycolysis to the tricarboxylic acid cycle.

View Article and Find Full Text PDF

A new anti-vascular endothelial growth factor agent, brolucizumab, was approved by the United States Food and Drug Administration in 2019. We evaluated whether brolucizumab reduces the treatment burden of neovascular age-related macular degeneration (nAMD) after switching by examining 1-year treatment outcomes in a real-world setting. This retrospective single-institution study included 107 consecutive eyes with nAMD treated with brolucizumab.

View Article and Find Full Text PDF

In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. The IMvigor130 trial reveals more favorable effects with atezolizumab combined with gemcitabine and cisplatin (GemCis) versus gemcitabine and carboplatin (GemCarbo). This study investigates the immunomodulatory effects of cisplatin as a potential explanation for these observations.

View Article and Find Full Text PDF

Background & Aims: Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic cytokines, are well-known. Whether sex influences the efficacy and safety of immunotherapy is not known.

Methods: We performed a restricted maximum likelihood random effects meta-analysis of five phase III trials that evaluated immune checkpoint inhibitors (ICIs) in advanced HCC and reported overall survival (OS) hazard ratios (HRs) stratified by sex to evaluate sex-related differences in OS.

View Article and Find Full Text PDF

Glycidol fatty acid esters that are present in foods are degraded in vivo to the animal carcinogen glycidol, which binds to the -terminal valine of hemoglobin (Hb) to form -(2,3-dihydroxypropyl)valine (diHOPrVal) adducts. The existence of other chemicals that are converted to glycidol is unknown. To determine the effect of different exposure conditions on the formation of diHOPrVal adducts, several glycidol-related chemicals (3-monochloropropane-1,2-diol; 3-MCPD, epichlorohydrin, glyceraldehyde, acrylic acid, and 1,2-propanediol) were evaluated using in vitro and in vivo (single/repeated dose) methods.

View Article and Find Full Text PDF